Skip to main content

Advertisement

Table 1 Association of COX-2 expression in NSCLC with clinical and pathologic factors (χ2 test)

From: Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer

  Total COX-2 low expression n(%) COX-2 high expression n(%) P
Sex     
   Male 63 33 (52.4) 30 (47.6) 0.803
   Female 21 12 (57.1) 9 (42.9)  
Age     
   ≤60 years 44 23 (52.3) 21 (47.7) 0.830
   > 60 years 40 22 (55.0) 18 (45.0)  
Smoking     
   Yes 38 21 (55.3) 17 (44.7) 0.828
   No 46 24 (52.2) 22 (47.8)  
Differentiation     
   Well and moderate 40 20 (50.0) 20 (50.0) 0.662
   Poor 44 25 (56.8) 19 (43.2)  
TNM stage     
   I 44 21 (47.7) 23 (52.3) 0.357
   II 19 10 (52.6) 9 (47.4)  
   III + IV 21 14 (66.7) 7 (33.3)  
Histology     
   Adeno 34 18 (52.9) 16 (47.1) 0.561
   SCC 45 23 (51.1) 22 (48.9)  
   Large cell carcinoma 5 4 (80.0) 1 (20.0)  
VEGF expression     
   High 42 12 (28.6) 30 (71.4) 0.000
   Low 42 33 (78.6) 9 (21.4)  
MVD expression     
   High 28 10 (35.7) 18 (64.3) 0.036
   Low 56 35 (62.5) 21 (37.5)  
  1. Abbreviations: Adeno, adenocarcinoma; SCC, squamous cell carcinoma.